Work

Prognostic value of point-of-care testing for cardiac myosin-binding protein C in early risk assessment of acute myocardial infarction: a prospective cohort study

Year: 2026

Type: article

Abstract: The prognostic value of myocardial myosin-binding protein C (cMyC) in acute myocardial infarction (AMI) remains insufficiently studied. To evaluate the association between admission cMyC levels and the risk of 30-day major adverse cardiovascular events (MACE) in patients with AMI. In this prospective, single-center study, patients with AMI admitted between March 2022 and July 2024 were included. cMyC and hs-cTnI were measured by point-of-care testing (POCT) at admission. The primary endpoint was 30-day MACE. Predictive performance was evaluated using ROC analysis and multivariable Cox regression. A total of 285 patients were included, with a 30-day MACE incidence of 27.4%. Admission cMyC was independently associated with 30-day MACE after adjustment for clinical covariates. Exploratory analyses suggested a graded association between cMyC levels and the risk of adverse outcomes. Admission cMyC measured by POCT was independently associated with 30-day MACE in patients with AMI. cMyC may serve as a rapid adjunctive biomarker for early risk stratification, although its incremental predictive value requires further validation.

Source: Scientific Reports

DOI: 10.1038/s41598-026-47454-1

Authors: Zengguang Chen, Jing Huang, Jing Wang, Yiyang Zhan, Qianwei Sun

Institutions: Changzhou No.2 People's Hospital, Nanjing Medical University, Jiangsu University, Jiangsu Province Hospital, Affiliated Hospital of Xuzhou Medical College

Language: English

Topic: Acute Myocardial Infarction Research

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,690